Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Cirrhosis

  Free Subscription


1 Clin Res Hepatol Gastroenterol
1 Intern Med
3 J Gastroenterol Hepatol
8 J Hepatol
2 Minerva Gastroenterol (Torino)
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Clin Res Hepatol Gastroenterol

  1. MOGA L, Robic MA, Blasco-Perrin H, Cabarrou P, et al
    Acute kidney injury in patients with cirrhosis: prospective longitudinal study in 405 patients.
    Clin Res Hepatol Gastroenterol. 2021 Oct 27:101822.
    PubMed         Abstract available

    Intern Med

  2. SHIGEFUKU R, Iwasa M, Eguchi A, Tempaku M, et al
    Serum Copeptin and Zinc-alpha2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Intern Med. 2021;60:3359-3368.
    PubMed         Abstract available

    J Gastroenterol Hepatol

  3. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed         Abstract available

  4. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed         Abstract available

  5. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed         Abstract available

    J Hepatol

  6. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.

  7. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.

  8. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.

  9. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed         Abstract available

  10. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.

    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.

  12. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    PubMed         Abstract available

  13. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    PubMed         Abstract available

    Minerva Gastroenterol (Torino)

  14. TESTINO G, Pellicano R
    Acute-on-chronic liver failure by SARS-CoV-2 in active alcohol use disorder cirrhotic patient.
    Minerva Gastroenterol (Torino). 2021;67:283-288.
    PubMed         Abstract available

  15. SCIARRONE SS, Zanetto A, Russo FP, Germani G, et al
    Malnourished cirrhotic patient: what should we do?
    Minerva Gastroenterol (Torino). 2021;67:11-22.
    PubMed         Abstract available

    PLoS One

  16. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.